Astrazeneca Share News (AZN)

UPDATE 1-AstraZeneca smashes forecasts in Q2 after seeing off Pfizer

* Q2 revenue $6.45 billion vs consensus $6.29 billion * Q2 core EPS $1.30 vs consensus $1.10 * Drugmaker raises full-year guidance * Now assuming generic Nexium in U.S. from Oct. 1 (Adds detail on products, background) By Ben Hirschler LONDON, July 31 (Reuters) - A

MARKET COMMENT: UK Stocks To Open Higher With Earnings In Focus

AstraZeneca smashes forecasts in Q2 after seeing off Pfizer

LONDON, July 31 (Reuters) - AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago. Sales in the first quarter rose 4 percent to $6.45 billion, des

UK Earnings, Trading Statements Calendar - Week Ahead

MARKET COMMENT: UK Stocks Fall As US GDP Surge Turns Attention To Fed

UK Earnings, Trading Statements Calendar - Week Ahead

Sanofi, Regeneron drug cuts cholesterol in nine late-stage trials

* Sanofi to file drug for US and EU approval by year-end * Nine Phase III ODYSSEY trials meet primary endpoint * Alirocumab "generally well tolerated" in trials By Natalie Huet PARIS, July 30 (Reuters) - A new drug being developed by French drugmaker Sanofi and U.S. partne

London midday: UK stocks flat ahead of US data, Fed decision

- Corporate earnings receive mixed market reaction - Barclays, Travis Perkins and Astra rise - Antofagasta, ITV and Compass fall - US data, Fed decision in focus later on techMARK 2,783.73 +0.05% FTSE 100 6,803.99 -0.06% FTSE 250 15,675.20 -0.08% The FTSE 100 was trading broadly flat on Wednesday,

UK MIDDAY BRIEFING: Barclays Leads FTSE 100 After Unexpected Profit Rise

UPDATE 3-AstraZeneca buys Almirall lung drugs for up to $2.1 billion

* Initial $875 mln payout, up to $1.22 bln more if goals hit * AstraZeneca gets access to Eklira and pipeline products * Disposal leaves Almirall focused on dermatology * Almirall shares jump 8 percent (Adds drug sales figure, Actavis role, Almirall ownership) By Ben Hir

UK WINNERS & LOSERS: Barclays Beat Sends Banks Higher

TOP NEWS: Barclays Beats Forecasts, Astra Buys Respiratory Business

London open: Stocks slip as investors digest earnings, Barclays rises

- Barclays rises as investors digest wave of corporate earnings - Russian sanctions, Gaza and Argentina in focus - US economic data, Fed decision due out later on techMARK 2,785.48 +0.12% FTSE 100 6,797.66 -0.15% FTSE 250 15,671.08 -0.10% UK markets opened slightly lower on Wednesday as investors

Astrazeneca to gain rights to Almirall's respiratory franchise

Astrazeneca has struck a deal with drug developer Almirall for the rights to the Spanish group's respiratory franchise. Under the agreement, which includes an initial consideration of $875m, the FTSE 100-listed company will gain the rights for the development and commercialisation of Almirall's ex

UPDATE 2-AstraZeneca buys Almirall lung drugs for up to $2.1 billion

* Almirall to get initial $875mln, up to $1.22bln in milestones * AstraZeneca gets access to Eklira and pipeline products * Almirall shares jump 8 percent (Adds analyst reaction, shares,) By Ben Hirschler LONDON, July 30 (Reuters) - AstraZeneca took a major step to build